Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PARP Inhibitors in Ovarian Cancer

7 Mar 2018

Abstract excerpt

BACKGROUND: Treatment of Epithelial Ovarian Cancer (EOC), historically based on surgery and platinum doublet chemotherapy, is associated with high risk of relapse and poor prognosis for recurrent disease. In this landscape, the innovative treatment with PARP inhibitors (PARPis) demonstrated an outstanding activity in EOC, and is currently changing clinical practice in BRCA mutant patients. OBJECTIVES: The study...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Nuclear Structure and Function
Share to Ovarian cancer diagnosis and treatment
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29512470
DOI: 10.2174/1574892813666180305165256

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PARP Inhibitors in Ovarian CancerPMID 29512470Read ↗

PARP Inhibitors in Ovarian Cancer: A ReviewSemantic proximity Read ↗

The current status of PARP inhibitors in ovarian cancer.Semantic proximity Read ↗

PARP inhibitors in ovarian cancerSemantic proximity Read ↗

The promising PARP inhibitors in ovarian cancer therapy: From Olaparib to others.Semantic proximity Read ↗

PARP Inhibitors in the Management of Ovarian Cancer: ASCO GuidelineSemantic proximity Read ↗

Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?Semantic proximity Read ↗

PARP Inhibitors for Ovarian Cancer: Current Indications, Future Combinations, and Novel Assets in Development to Target DNA Damage RepairSemantic proximity Read ↗

PARP inhibitors in ovarian cancer.Semantic proximity Read ↗

Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancerSemantic proximity Read ↗

Current Ovarian Cancer Maintenance Strategies and Promising New DevelopmentsSemantic proximity Read ↗

What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?Semantic proximity Read ↗

Current status and future prospects of PARP inhibitor clinical trials in ovarian cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.